Welcome & Introduction
Dana Wollins, DrPH, MGC
Vice President, Clinical Affairs & Guidelines
IDSA

- 71st in a series of weekly calls, initiated by CDC as a forum for information sharing among frontline clinicians caring for patients with COVID-19

- The views and opinions expressed here are those of the presenters and do not necessarily reflect the official policy or position of the CDC or IDSA. Involvement of CDC and IDSA should not be viewed as endorsement of any entity or individual involved.

- This webinar is being recorded and can be found online at www.idsociety.org/cliniciancalls.
TODAY’S CALL:

More on the Delta Variant, CDC Masking Recommendations and Updates from ACIP

More on the Delta Variant & CDC Masking Recommendations

John T. Brooks, MD
Chief Medical Officer
COVID-19 Response
Centers for Disease Control and Prevention

Immunocompromise and COVID-19 Vaccine

Helen “Keipp” Talbot, MD, MPH
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Vanderbilt University Medical Center
Question?
Use the “Q&A” Button

Comment?
Use the “Chat” Button
CDC/IDSA COVID-19 Clinical Call: Immunocompromise & COVID-19 Vaccine

Keipp Talbot, MD MPH
July 31, 2021
Immunocompromised people & SARS-CoV-2 infection

- Immunocompromised people comprise ~2.7% of U.S. adults¹
- More likely to get severely ill from COVID-19
- Higher risk for:
  - Prolonged SARS-CoV-2 infection and shedding
  - Viral evolution during infection and treatment (hospitalized patients)
  - Low antibody/neutralization titers to SARS-CoV-2 variants
- More likely to transmit SARS-CoV-2 to household contacts
- More likely to have breakthrough infection
- Early VE reports range from 59% to 74%

Adapted from ACIP Data and Clinical Considerations for Additional Doses in Immunocompromised People Sara Oliver ACIP July 22, 2021
Percent of subjects with antibody response after **two** mRNA vaccine doses by immunocompromising condition and study (n=63)

- Studies that compared response after 1st and 2nd dose demonstrated poor response to dose 1
- Antibody measurement and threshold levels vary by study protocol

Darker blue color is hematologic cancers

Healthy Controls: 95%–100%

Adapted from ACIP Data and Clinical Considerations for Additional Doses in Immunocompromised People
Sara Oliver ACIP July 22, 2021
Comparing evidence 3rd mRNA COVID-19 vaccine dose in immunosuppressed people with seropositive response

<table>
<thead>
<tr>
<th>Study</th>
<th>Patient Population</th>
<th>2nd Dose</th>
<th></th>
<th>3rd Dose Seronegative after 2nd dose</th>
<th>Seropositive N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Sample Size</td>
<td>Seronegative N (%)</td>
<td>Seropositive N (%)</td>
<td>Sample Size</td>
</tr>
<tr>
<td>Kamar et al.</td>
<td>Recipients of solid-organ transplant</td>
<td>99</td>
<td>59 (60)</td>
<td>40 (40)</td>
<td>59</td>
</tr>
<tr>
<td>Werbel et al.*</td>
<td>Recipients of solid-organ transplant</td>
<td>30</td>
<td>24 (80)</td>
<td>6 (20)</td>
<td>24</td>
</tr>
<tr>
<td>Longlune et al.</td>
<td>Patients on hemodialysis</td>
<td>82</td>
<td>13 (16)</td>
<td>69 (84)</td>
<td>12</td>
</tr>
<tr>
<td>Maxime et al.</td>
<td>Patients on hemodialysis</td>
<td>106</td>
<td>66 (62)</td>
<td>40 (38)</td>
<td>12</td>
</tr>
</tbody>
</table>

* Recipients received homologous mRNA prime followed by either a single Moderna, Pfizer, or Janssen boost

- Among those who had **no detectable antibody** response to an initial mRNA vaccine series, **33-50% developed an antibody response to an additional dose**
TN COVID-19 Vaccination by County
Conclusions

Vaccine breakthrough does occur in those immunocompromised

Studies ongoing to see if a third dose provides better protection

Critically important to vaccinate those who interact with the immunocompromise
International policies on additional doses for immunocompromised people

**France**¹ (Announced April 11, 2021)
- 3rd dose 4 weeks after the 2nd dose for patients who are “severely immunocompromised”
- Could be extended at a later date to include a larger immunocompromised population

**United Kingdom**² (Announced July 1, 2021)
- Proposal for an additional dose for immunocompromised people ≥16 years (among others), to be implemented between 6 September and 17 December 2021
- Decision pending

**Israel**³ (Announced July 11, 2021)
- People living with organ or stem cell transplants, blood cancer, autoimmune disease and treatment with specific immunosuppressive medications
- People with breast, lung, or colon cancer do not qualify

---

¹ [solidarites-sante.gouv.fr]
² [C1327-covid-19-vaccination-autumn-winter-phadvicease-3-planning.pdf](https://govextra.gov.il/media/30095/meeting-summary-15122020.pdf)
³ Adapted from ACIP Data and Clinical Considerations for Additional Doses in Immunocompromised People Sara Oliver ACIP July 22, 2021
Q&A and Discussion
An online community bringing together information and opportunities for discussion on latest research, guidelines, tools and resources from a variety of medical subspecialties around the world.

Specialty Society Collaborators

- American Academy of Family Physicians
- American Academy of Pediatrics
- American College of Emergency Physicians
- American College of Physicians
- American Geriatrics Society
- American Thoracic Society
- Pediatric Infectious Diseases Society
- Society for Critical Care Medicine
- Society for Healthcare Epidemiology of America
- Society of Hospital Medicine
- Society of Infectious Diseases Pharmacists

www.COVID19LearningNetwork.org
@RealTimeCOVID19
#RealTimeCOVID19
FOR WHOM?
- Clinicians who have questions about the clinical management of COVID-19

WHAT?
- Calls from clinicians will be triaged by CDC to a group of IDSA volunteer clinicians for peer-to-peer support

HOW?
- Clinicians may call the main CDC information line at 800-CDC-INFO (800-232-4636)
- To submit your question in writing, go to www.cdc.gov/cdc-info and click on Contact Form
Attend, Learn & Collaborate.
Advancing Science, Improving Care

Save the Date
Sept. 29 – Oct. 3, 2021

Important Dates:
• Registration is Open
• Abstract Submission Deadline – June 9
• Case Submission Deadline – June 9
Continue the conversation on Twitter

@RealTimeCOVID19
#RealTimeCOVID19

We want to hear from you!
Please complete the post-call survey.
Clinician calls are now twice a month:

**Updated Summer Schedule:**

- August 14
- August 28

A recording of this call will be posted Monday at [www.idsociety.org/cliniciancalls](http://www.idsociety.org/cliniciancalls)

-- library of all past calls available --

**Contact Us:**
Dana Wollins (dwollins@idsociety.org)
Deirdre Lewis (dlewis@idsociety.org)
Infectiousness of the Delta Variant (B.1.617.2)

John T. Brooks
CDC COVID-19 Emergency Response
IDSA Saturday Call July 31, 2021
Current Situation
The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

https://covid.cdc.gov/covid-data-tracker/#trends_dailytrends
The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

https://covid.cdc.gov/covid-data-tracker/#trends_dailytrends

Daily Number of COVID-19 Cases and Deaths: United States Through 28 July 2021 - CDC COVID Data Tracker

Daily case count

7-day moving average

Cases

Deaths

https://covid.cdc.gov/covid-data-tracker/#trends_dailytrends

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Nationwide Cases are Rising Steeply By Over 400% in Weeks

https://covid.cdc.gov/covid-data-tracker/#trends_dailytrends

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Nationwide Cases are Rising Steeply By Over 400% in Weeks

July 6, 2021
24% of counties
at **substantial** to **high** levels of transmission

July 28, 2021
67% of counties
at **substantial** to **high** levels of transmission

https://covid.cdc.gov/covid-data-tracker/#trends_dailytrends

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
COVID-19 Case Rate (7-day rate per 100,000) By Percent of State Population Fully Vaccinated, July 22-28, 2021

Data Sources: Aggregate-level case surveillance notifications and aggregate-level vaccination information from state, local and territorial public health jurisdictions for the 50 US states and Puerto Rico, accessed July 30, 2021.

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
COVID-19 Case Rate (7-day rate per 100,000) By Percent of State Population Fully Vaccinated, July 22-28, 2021

Data Sources: Aggregate-level case surveillance notifications and aggregate-level vaccination information from state, local and territorial public health jurisdictions for the 50 US states and Puerto Rico, accessed July 30, 2021.

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
COVID-19 Case Rate (7-day rate per 100,000) By Percent of State Population Fully Vaccinated, July 22-28, 2021

Data Sources: Aggregate-level case surveillance notifications and aggregate-level vaccination information from state, local and territorial public health jurisdictions for the 50 US states and Puerto Rico, accessed July 30, 2021.

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Daily Number of COVID-19 Cases and Deaths: Louisiana Through 28 July 2021 - CDC COVID Data Tracker

https://covid.cdc.gov/covid-data-tracker/#trends_dailytrends

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

https://covid.cdc.gov/covid-data-tracker/#trends_dailytrends

The Daily Number of COVID-19 Cases and Deaths: Louisiana Through 28 July 2021 - CDC COVID Data Tracker

### Cases

- JAN 22
- APR 23
- JUL 24
- OCT 24
- JAN 24
- APR 26
- JUL 29

### Deaths

- JAN 22
- APR 23
- JUL 24
- OCT 24
- JAN 24
- APR 26
- JUL 29
Vaccination Coverage Remains Low, Especially in High Transmission Areas

Counties by Percentage of the Population Fully Vaccinated and 7-Day Case Rate

https://emergency.cdc.gov/han/2021/han00447.asp

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Vaccine Effectiveness Against Variant Infection
SARS-CoV-2 Variants Circulating in the United States

Collection date, two weeks ending

**These data include Nowcast estimates, which are modeled projections that may differ from weighted estimates generated at later dates.**

Other represents lineages each circulating at <1% of viruses over the last 4 weeks of weighted data.

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Effectiveness of COVID-19 Vaccines Against Variants

Against symptomatic disease:
• 94% effective for Alpha
• 88% effective for Delta
(For BNT162b2, mRNA)

Against hospitalization:
• 95% effective for Alpha
• 96% effective for Delta
(For BNT162b2, mRNA)

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Published July 21, 2021

Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant

Posted June 14, 2021
Risk of Delta Transmission
Before Vaccination (Unvaccinated)
**Cycle Threshold Values: Unvaccinated Persons**

Median cycle threshold values for 2,349 patients among 4,920 for whom variant type was known (includes approximately 6.5% fully vaccinated persons)

<table>
<thead>
<tr>
<th>PCR Platform</th>
<th>Delta Variant</th>
<th>Other Variants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott Alinity</td>
<td>20.67 (n = 326)</td>
<td>24.09 (n = 1598)</td>
</tr>
<tr>
<td>(n = 1924)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hologic Panther</td>
<td>21.10 (n = 88)</td>
<td>24.50 (n = 513)</td>
</tr>
<tr>
<td>(n = 601)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In unvaccinated persons, Delta infection achieves lower Ct values than non-Delta variants.
Secondary Infections

Secondary attack rates amongst household and non-household contacts of non-travel cases of Alpha and Delta, with 95% confidence intervals (29 MAR 2021 to 27 JUN 2021)

In a general population, Delta variant infections about twice as infectious as infections with non-Delta variants.
Secondary Infections

Secondary attack rates amongst household and non-household contacts of non-travel cases of Alpha and Delta, with 95% confidence intervals (29 MAR 2021 to 27 JUN 2021)

In a general population, Delta variant infections about twice as infectious as infections with non-Delta variants
Secondary Infections

Secondary attack rates amongst household and non-household contacts of non-travel cases of Alpha and Delta, with 95% confidence intervals (29 MAR 2021 to 27 JUN 2021)

In a general population, Delta variant infections about twice as infectious as infections with non-Delta variants
Risk of Delta Transmission After Vaccination (Vaccinated)
The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Average Ct values*

Delta 16.5
Non-Delta 19.0

In vaccinated persons, Delta infection appears to also achieve lower Ct values than non-Delta variants.

* The vaccine used was Covishield (ChAdOx1), which is not available in the U.S.
Secondary Infections: Vaccinated Persons

Investigators in India assessed secondary infections among HCW associated breakthrough infections

- Non-Delta variant infections in HCW mean cluster size: 1.1 persons
- Delta variant infections in HCW mean cluster size: 3.3 persons

No clusters of non-Delta infections comprising >2 individuals, whereas there were ten such clusters for Delta variant.

In vaccinated persons, Delta infections appeared more infectious than non-Delta variants based on secondary infections.

Mlochova et al. 2021, SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough | Research Square

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Risk of Delta Transmission
Unvaccinated vs. Vaccinated People Compared
Infections in Unvaccinated vs. Vaccinated Compared

HEROES-RECOVER Cohorts

- 3,975 healthcare personnel and other essential and frontline workers
- Provide weekly NP swabs
- SARS-CoV-2 confirmed in 204 persons
- Compared laboratory and clinical illness characteristics in unvaccinated (n=155) and partially (n=11) or fully vaccinated (n=5)

Table 3. Viral RNA Load, Duration of Viral RNA Detection, Frequency of Febrile Symptoms, and Duration of Illness in Vaccinated and Unvaccinated Participants with SARS-CoV-2 Infection.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Unvaccinated</th>
<th>Partially or Fully Vaccinated</th>
<th>Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral RNA load</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. assessed</td>
<td>155</td>
<td>16</td>
<td>—</td>
</tr>
<tr>
<td>Mean [log_{10} ] copies/ml†</td>
<td>3.8±1.7</td>
<td>2.3±1.7</td>
<td>40.2 (16.3–57.3)‡</td>
</tr>
<tr>
<td>Duration of viral RNA detection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. assessed</td>
<td>155</td>
<td>16</td>
<td>—</td>
</tr>
<tr>
<td>Mean — days</td>
<td>8.9±10.2</td>
<td>2.7±3.0</td>
<td>6.2 (4.0–8.4)‡</td>
</tr>
<tr>
<td>Detection of viral RNA for &gt;1 week — no./total no. (%)</td>
<td>113/156 (72.4)</td>
<td>4/16 (25.0)</td>
<td>0.34 (0.15–0.81)§</td>
</tr>
<tr>
<td>Febrile symptoms — no./total no. (%)</td>
<td>94/149 (63.1)</td>
<td>4/16 (25.0)</td>
<td>0.42 (0.18–0.98)§</td>
</tr>
<tr>
<td>Total days of symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. assessed</td>
<td>148</td>
<td>16</td>
<td>—</td>
</tr>
<tr>
<td>Mean — days</td>
<td>16.7±15.7</td>
<td>10.3±10.3</td>
<td>6.4 (0.4–12.3)</td>
</tr>
<tr>
<td>Days spent sick in bed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. assessed</td>
<td>147</td>
<td>15</td>
<td>—</td>
</tr>
<tr>
<td>Mean — days</td>
<td>3.8±5.9</td>
<td>1.5±2.1</td>
<td>2.3 (0.8–3.7)</td>
</tr>
</tbody>
</table>


The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Infections in Unvaccinated vs. Vaccinated Compared

<table>
<thead>
<tr>
<th>Variable</th>
<th>Unvaccinated</th>
<th>Partially or Fully Vaccinated</th>
<th>Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral RNA load</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. assessed</td>
<td>155</td>
<td>16</td>
<td>—</td>
</tr>
<tr>
<td>Mean — log_{10} copies/ml†</td>
<td>3.8±1.7</td>
<td>2.3±1.7</td>
<td>40.2 (16.3–57.3)‡</td>
</tr>
<tr>
<td>Duration of viral RNA detection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. assessed</td>
<td>155</td>
<td>16</td>
<td>—</td>
</tr>
<tr>
<td>Mean — days</td>
<td>8.9±10.2</td>
<td>2.7±3.0</td>
<td>6.2 (4.0–8.4)</td>
</tr>
<tr>
<td>Detection of viral RNA for &gt;1 week — no./total no. (%)</td>
<td>113/156 (72.4)</td>
<td>4/16 (25.0)</td>
<td>0.34 (0.15–0.81)§</td>
</tr>
<tr>
<td>Febrile symptoms — no./total no. (%) ¶</td>
<td>94/149 (63.1)</td>
<td>4/16 (25.0)</td>
<td>0.42 (0.18–0.98)</td>
</tr>
<tr>
<td>Total days of symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. assessed</td>
<td>148</td>
<td>16</td>
<td>—</td>
</tr>
<tr>
<td>Mean — days</td>
<td>16.7±15.7</td>
<td>10.3±10.3</td>
<td>6.4 (0.4–12.3)</td>
</tr>
<tr>
<td>Days spent sick in bed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. assessed</td>
<td>147</td>
<td>15</td>
<td>—</td>
</tr>
<tr>
<td>Mean — days</td>
<td>3.8±5.9</td>
<td>1.5±2.1</td>
<td>2.3 (0.8–3.7)</td>
</tr>
</tbody>
</table>

HEROES-RECOVER Cohorts

Vaccinated breakthroughs:
- **Lower** viral load
- RNA detection **resolved faster**
- **Less symptomatic**
- **Shorter** illness duration
- **Fewer sick days** in bed


The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

**Pace of Infection in Terms of Viral Load**

**Estimated Viral Load Growth Rate in Unvaccinated Quarantined Patients**

- **Days to first PCR detection**
  - 19A/19B (n=29): 6 (IQR 5-8)
  - Delta (n=34): 4 (IQR 3-5)

- **Delta variant**
  - RNA is detected earlier
  - Ct values peak earlier*

  *for 19A/B 5.61 days, for Delta 3.71 days

**With Delta infection:**
- RNA is detected earlier
- Ct values peak earlier*

The incubation period of infection may be shorter, but duration of infectiousness remains unknown.
Delta vs. Other SARS-CoV-2 Variants

- **In unvaccinated** people without prior infection:
  - Delta achieves a higher viral load than other variants
  - Delta is about twice as infectious as other variants

- **In vaccinated** people with breakthrough infections:
  - Delta also achieves a higher viral load than other variants
  - How much more infectious Delta is remains unknown at this time

---


Investigation of SARS-CoV-2 variants of concern: technical briefings - GOV.UK
(www.gov.uk)

Li et al. 2021, *medRxiv*: Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant *medRxiv*.

Musser et al. 2021, *medRxiv*: Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas *medRxiv*.

Mlcochova et al. 2021, *Research Square*: SARS-CoV-2 B.1.617.2 Delta variant emergence and vaccine breakthrough
Delta vs. Other SARS-CoV-2 Variants

- In *unvaccinated* people without prior infection:
  - Delta achieves a higher viral load than other variants
  - Delta is about twice as infectious as other variants

- In *vaccinated* people with breakthrough infections:
  - Delta also achieves a higher viral load than other variants
  - How much more infectious Delta is remains unknown at this time

How do the viral loads in unvaccinated and vaccinated people compare if they are infected with the same variants?
Infections in Unvaccinated and Vaccinated Compared

Data from CDC Cohorts

- No Delta infections**
- Viral load has been lower in vaccinated people who get infected than in unvaccinated people
- Vaccinated less infectious than unvaccinated

** In unvaccinated persons: 10 variants of concern (VOC): 9 B.1.427/9 and 1 B.1.1.7 (alpha). In vaccinated, 3 VOCs all B.1.429.

*mean viral load ± standard deviation


The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Infections in Unvaccinated and Vaccinated Compared

Data from Barnstable, MA Outbreak*
- All Delta infections (as of July 25, 2021)
- Viral load** the same in both vaccinated unvaccinated people with infection
- Vaccinated *equally* infectious as unvaccinated

* 469 Massachusetts cases investigated of whom 364 (74%) vaccinated. Four breakthroughs (1.1%) hospitalized (two with underlying medical conditions), no deaths.

** Data presented are Ct values that in aggregate generally correlate with viral burden.

Brown et al. 2021, MMWR: https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7031e2-H.pdf

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Delta Variant Infection Produces High Viral Loads Compared with Other Variant Infections

Data from 846 Diagnoses Infection with Variant and Wild Type - Singapore

1 January 2021 – 22 May 2021

Ong et al. 2021, medRxiv: Retrospective cohort study comparing clinical and virological features B.1.1.7 (Alpha), B.1.315 (Beta) B.1.617.2 (Delta) Singapore

The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Infections in Unvaccinated and Vaccinated Compared

Data from Dane County WI and Surrounding Counties Served Laboratory
28 June 2021 – 24 July 2021, When Delta Was Predominant Variant

Riemersma et al. 2021, medRxiv: Vaccinated and unvaccinated individuals have similar viral loads in communities with a high prevalence of the SARS-CoV-2 delta variant.
Infections in Unvaccinated and Vaccinated Compared

Data from 218 Patients Admitted with Delta Variant Infections - Singapore

1 April 2021 – 15 June 2021


The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Infections in Unvaccinated and Vaccinated Compared

Data from 218 Patients Admitted with Delta Variant Infections - Singapore

1 April 2021 – 15 June 2021


The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Despite Delta, FDA Authorized Vaccines Still Work

- Despite these developments, vaccination continues to save lives
- Vaccine effectiveness (VE) might be decreasing for symptomatic illness
- However, all evidence indicates high levels VE against severe illness or death after full vaccination with Pfizer or Moderna product
  - Data more limited for J&J
- Increasing vaccination coverage remains the number one priority to reduce transmission as well reducing the risk of more emerging variants
Topline Messages

1. Getting vaccinated prevents severe illness, hospitalization, and death; it also helps reduce the spread of the virus in communities.
   • Unvaccinated individuals should get vaccinated and continue masking until they are fully vaccinated.
   • With the Delta variant, this is more urgent than ever. The highest spread of cases and severe outcomes is happening in places with low vaccination rates.
Topline Messages

2. Data show Delta is different than past versions of the virus: it is much more contagious.
   - Some vaccinated people can get Delta in a breakthrough infection and may be contagious.
   - Even so, vaccinated individuals represent a very small amount of transmission occurring around the country.
   - Virtually all hospitalizations and deaths continue to be among the unvaccinated.
Topline Messages

3. In areas with substantial and high transmission, **CDC recommends that everyone (including fully vaccinated individuals) wear a mask in public indoor settings** to help prevent spread of Delta and protect others.
Topline Messages

3. In areas with substantial and high transmission, **CDC recommends that everyone (including fully vaccinated individuals) wear a mask in public indoor settings** to help prevent spread of Delta and protect others.

4. **CDC recommends that community leaders encourage vaccination and masking** to prevent further outbreaks in areas of substantial and high transmission.
Topline Messages

3. In areas with substantial and high transmission, **CDC recommends that everyone (including fully vaccinated individuals) wear a mask in public indoor settings** to help prevent spread of Delta and protect others.

4. **CDC recommends that community leaders encourage vaccination and masking** to prevent further outbreaks in areas of substantial and high transmission.

5. **CDC recommends universal indoor masking for all teachers, staff, students, and visitors to K-12 schools, regardless of vaccination status.** Children should return to full-time in-person learning in the fall with layered prevention strategies in place.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.